程序性死亡受体1及其配体在三阴性乳腺癌中的表达及诊断价值

Expression and diagnostic value of PD-1/PD-L1 in triple negative breast cancer

目的分析程序性死亡受体1(PD-1)及配体1(PD-1/PD-L1)在三阴性乳腺癌(TNBC)中的表达及诊断价值。方法收集70例TNBC患者(试验组)、60例非TNBC患者(阳性对照组)、20例乳腺良性疾病患者(阴性对照组)的临床资料,采用免疫组织化学法检测乳腺癌组织PD-1和PD-L1蛋白表达情况,比较分析各组PD-1和PD-I阳性表达率,及其与临床病理特征、临床分型的关系。结果试验组和阳性对照组PD-1和PD-L1阳性表达率均显著高于阴性对照组,而试验组PD-1和PD-L1阳性表达率均显著高于阳性对照组(P<0.05)。TNBC患者PD-1和PD-L1蛋白阳性率与病理分期、淋巴转移有关(P<0.05)。Luminal A型、Luminal B型、原癌基因人表皮生长因子受体(HER)2过表达型的非TNBC患者PD-1和PD-L1阳性表达率比较,差异均无统计学意义(P>0.05)。结论TNBC患者PD-1/PD-L1呈相对高表达状态,且与病变程度相关,可作为TNBC早期诊断的生物标志物,阻断PD-1/PD-L1表达有望成为TNBC新的治疗靶点。

Objective To investigate the expression and diagnostic value of programmed death receptor-1/programmed death receptor ligand-1(PD-1/PD-L1)in triple negative breast cancer(TNBC).Methods Clinical data of 70 patients with TNBC(experimental group),60 patients with non-TNBC(positive control group)and 20 patients with benign breast disease(negative control group)were collected.Immunohistochemical method was used to detect the protein expression of PD-1 and PD-L1 in breast cancer tissues,the positive expression rates of PD-1 and PD-L1 in each group,and their relationship with clinicopathological characteristics and clinical classification were compared and analyzed.Results The positive expression rates of PD-1 and PD-L1 in experimental group and positive control group were significantly higher than those in negative control group,while the positive expression rates of PD-L1 and PD-L1 in experimental group were significantly higher than those in positive control group(P<0.05).The positive rates of PD-1 and PD-L1 proteins in TNBC patients were significantly correlated with pathological stages and lymphatic metastasis(P<0.05).There was no statistical significance in the positive expression rates of PD-1 and PD-L1 among patients with Luminal A type,Luminal B type and HER 2 overexpression type(P>0.05).Conclusions The expression of PD-1/PD-L1 is relatively high in patients with TNBC,which is correlated with the degree of lesion,and can be used as a biomarker for early diagnosis of TNBC.Blocking the expression of PD-1/PD-L1 is expected to become a new therapeutic target for TNBC.